. 2018 Aug 23;7(3):119–123. doi: 10.4103/GMIT.GMIT_35_18

Table 2.

Changes of symptoms and biomarker in the gonadotropin-releasing hormone agonist, low-dose estrogen-progestin combination, and dienogest treatment groups

	GnRHa (26)		LEP (15)		DNG (11)

	Before	After 16 weeks of treatment	Before	After 16 weeks of treatment	Before	After 16 weeks of treatment
Menorrhagia^b	16 (61.5)	0	9 (56.3)	7 (46.7)	4 (36.4)	2 (18.2)
Dysmenorrhea^b	9 (34.6)	0	9 (56.3)	6 (40.0)	2 (18.2)	0
Chronic pelvic pain^b	6 (23.1)	1 (3.8)	2 (12.5)	1 (6.3)	4 (36.4)	2 (18.2)
CA125 (U/mL)^a	203.1	36.5*	237.5	25.2*	255.9	26.4*

^aValues are given as mean, ^bValues are given as n (%), *P<0.01. GnRHa: Gonadotropin-releasing hormone agonist, LEP: Low-dose estrogen-progestin combination, DNG: Dienogest, CA125: Carcinoma antigen 125